Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Janssen’

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely active Crohn’s disease in adults who have proved unresponsive to conventional therapy or a TNFα inhibitor.

Bron: Pharmafile Meer lezen »

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate to severe plaque psoriasis, showing the drug to produce significant efficacy compared to Abbvie’s blockbuster drug and market leader Humira (adalimumab).  

Bron: InPharm.com Meer lezen »

Janssen reveals positive results from longest follow-up of Imbruvica

Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica (ibrutinib) had demonstrated an overall response rate of 89% in patients suffering from chronic lymphocytic leukaemia (CLL). The results from the trial also saw 29% of patients have a complete response to first-line treatment.

Bron: InPharm.com Meer lezen »

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.  

Bron: InPharm.com Meer lezen »

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  

Bron: InPharm.com Meer lezen »

AbbVie, Janssen’s Imbruvica gets European approval to teat CLL

AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. This is the fifth indication for the drug in the EU, which is co-developed by Janssen and AbbVie.  

Bron: InPharm.com Meer lezen »

Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials

Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials. The company said a significant number of patients with Crohn’s disease receiving its Stelara (ustekinumab) were in clinical remission at one year in Phase III trials.

Bron: InPharm.com Meer lezen »

Janssen inks pact with Tesaro for prostate cancer

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered a worldwide collaboration and license agreement with Tesaro, Inc., for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase (PARP) inhibitor, currently in late-stage development for patients with metastatic breast cancer and […]

Bron: Pharma Biz Meer lezen »

NICE approves Janssen’s Zytiga for prostate cancer before chemo

The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat relapsed prostate cancer that has spread prior to chemotherapy.  

Bron: InPharm.com Meer lezen »

Janssen’s Zytiga boosts survival in early-stage prostate cancer

Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall survival (OS) by 11.8 months compared placebo plus prednisone, in men with early and less aggressive metastatic castration-resistant prostate cancer (mCRPC) who had not received chemotherapy.

Bron: InPharm.com Meer lezen »

« Oudere artikelen |